Apremilast, a novel oral phosphodiesterase-4 inhibitor, is now available for the treatment of psoriatic arthritis in the US. In a randomized trial, apremilast decreased disease activity and improved functional ability at 16 weeks more than placebo. It is not yet known whether apremilast can prevent or reduce joint damage from psoriatic arthritis. For related UpToDate “What’s New” content and the supporting evidence click here:
Posted on: Tue, 06 May 2014 13:15:06 +0000
Trending Topics
Recently Viewed Topics
© 2015